top of page

NARLA

LAB

Published Papers

02 / 16 / 2026

The protein phosphatase 2A-B56α complex regulates N-Myc degradation in neuroblastoma

10 / 14 / 2025

A PP2A molecular glue overcomes RAS/MAPK inhibitor resistance in KRAS-mutant non–small cell lung cancer

02 / 01 / 2025

Mutant PP2A Induces IGFBP2 Secretion to Promote Development of High-Grade Uterine Cancer

11 / 01 / 2022

Biased holoenzyme assembly of Protein Phosphatase 2A (PP2A): from cancer to small molecules

12 / 17 / 2021

Targeting ribonucleotide reductase induces synthetic lethality in PP2A-deficient uterine serous carcinoma

07 / 16 / 2021

Targeting protein phosphatase PP2A for cancer therapy: development of allosteric pharmaceutical agents

10 / 07 / 2020

The SRG rat, a Sprague-Dawley Rag2/Il2rg double-knockout validated for human tumor oncology studies

04 / 20 / 2020

Selective PP2A Enhancement through Biased Heterotrimer Stabilization

12 / 10 / 2019

Protein phosphatase 2A activation as a therapeutic strategy for managing MYC-driven cancers

09 / 27 / 2019

Protein phosphatase 2A controls ongoing DNA replication by binding to and regulating cell division cycle 45 (CDC45)

09 / 20 / 2019

Inactivation of PP2A by a recurrent mutation drives resistance to MEK inhibitors

05 / 29 / 2019

The Highly Recurrent PP2A Aα-Subunit Mutation P179R Alters Protein Structure and Impairs PP2A Enzyme Function to Promote Endometrial Tumorigenesis

07 / 17 / 2018

PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells

04 / 01 / 2018

Small-Molecule Activators of Protein Phosphatase 2A for the Treatment of Castration-Resistant Prostate Cancer

10 / 08 / 2017

Therapeutic targeting of PP2A

10 / 28 / 2015

All roads lead to PP2A: Exploiting the therapeutic potential of this phosphatase

Read all published papers from the Narla Lab here.

bottom of page